ProCE Banner Activity

My Thoughts on the Clinical Advances in Diagnostics for FGFR Alterations in Cancer

Clinical Thought
Expert faculty discusses FGFR signaling, possible consequences of FGFR alterations in tumor development, and current FGFR testing methods and prognostic value.

Released: April 09, 2021

Expiration: April 08, 2022

No longer available for credit.

Share

Faculty

Prof. Dr. Arndt Hartmann

Prof. Dr. Arndt Hartmann

Professor
Institute of Pathology
Friedrich-Alexander-Universität Erlangen-Nürnberg
Chairman
Institute of Pathology
University Clinic Erlangen
Friedrich-Alexander Universitat
Erlangen, Germany

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Pharmaceutica NV

Faculty Disclosure

Primary Author

Prof. Dr. Arndt Hartmann,

Professor
Institute of Pathology
Friedrich-Alexander-Universität Erlangen-Nürnberg
Chairman
Institute of Pathology
University Clinic Erlangen
Friedrich-Alexander Universitat
Erlangen, Germany

Professor Arndt Hartmann has disclosed that he has received consulting fees from Agilent, AstraZeneca, Bristol-Myers Squibb, Diaceutics, Janssen, MSD, Pfizer, and Roche.